Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 and Anlotinib in Advanced Acral Malignant Melanoma
NCT03991975Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2019
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart in acral lentiginous melanoma (ALM), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
benmelstobart
03
Conditions
acral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on NCT03991975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03991975.